Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

BCRX stock hub

BioCryst Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BCRXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

2.2B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

BCRX

In the news

Latest news · BCRX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E29.8

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC431.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BCRX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

229

Groups with data

Currency

USD

Showing 229 of 229 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000882796
Company name	BioCryst Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	09058V103
Employees	435
Employees Change	-145%
Employees Change Percent	-25
Enterprise value	$2.8B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	1994-03-03
Isin	US09058V1035
Last refreshed	2026-05-10
Market cap	$2.2B
Market cap category	Mid-Cap
Price	$8.62
Price currency	USD
Rev Per Employee	2,036,128.74x
Sector	Healthcare
Sic	2836
Symbol	BCRX
Website	https://www.biocryst.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-20.9%
EV Sales Forward	4.18x
EV/EBIT	8.72x
EV/EBITDA	8.61x
EV/FCF	9.06x
EV/Sales	3.17x
FCF yield	14.17%
Forward P/E	29.78x
P/S ratio	2.47x
PS Forward	3.26x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	36.38%
EBITDA Margin	36.86%
FCF margin	35.04%
Gross margin	76.63%
Gross Profit	$678.7M
Gross Profit Growth	109.67%
Gross Profit Growth Q	-12.52%
Gross Profit Growth3 Y	145.16%
Net Income	$-458M
Net Income Growth Years	3%
Pretax Margin	-51.28%
Profit Margin	-51.71%
Profit Per Employee	$-1.1M
Profitable Years	1
ROA	42.62
Roa5y	-1.78
ROCE	119.5
ROIC	431.8

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	11.74%
Cagr15y	6.35%
Cagr1y	-14.49%
Cagr20y	-2.69%
Cagr3y	0.23%
Cagr5y	-8.06%
EPS Growth Years	3
Revenue Growth	75.92x
Revenue Growth Q	7.48x
Revenue Growth Quarters	21x
Revenue Growth Years	5x
Revenue Growth3 Y	45.14x
Revenue Growth5 Y	94.22x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$1.87
Assets	$465.1M
Cash	$238.4M
Current Assets	$373.6M
Current Liabilities	$195.4M
Debt	$858.1M
Debt EBITDA	$2.61
Debt FCF	$2.76
Equity	$-553.8M
Interest Coverage	4.29
Liabilities	$1B
Long Term Assets	$91.4M
Long Term Liabilities	$823.5M
Net Cash	$-619.7M
Net Cash By Market Cap	$-28.28
Net Debt EBITDA	$1.9
Net Debt FCF	$2
Tangible Book Value	$-553.8M
Tangible Book Value Per Share	$-2.18
WACC	7.25

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.91
Inventory Turnover	32.2
Net Working Capital	$-16.8M
Quick ratio	1.78
Working Capital	$178.2M
Working Capital Turnover	$3.95

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-5.23%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	203.52%
1Y total return	-14.48%
200-day SMA	7.89
3Y total return	0.7%
50-day SMA	9.13
50-day SMA vs 200-day SMA	50over200
5Y total return	-34.3%
All Time High	37.25
All Time High Change	-76.86%
All Time High Date	2000-03-09
All Time Low	0.6
All Time Low Change	1,336.67%
All Time Low Date	2002-06-26
ATR	0.45
Beta	0.57
Beta1y	-0.02
Beta2y	0.57
Ch YTD	10.51
High	8.99
High52	11.31
High52 Date	2025-06-04
High52ch	-23.78%
Low	8.56
Low52	6
Low52 Date	2025-10-14
Low52ch	43.67%
Ma50ch	-5.55%
Premarket Change Percent	1.01
Premarket Price	$8.99
Premarket Volume	22,818
Price vs 200-day SMA	9.31%
RSI	40.98
RSI Monthly	52.07
RSI Weekly	53.51
Sharpe ratio	-0.25x
Sortino ratio	-0.24
Total Return	-5.23%
Tr YTD	10.51
Tr15y	151.68%
Tr1m	-10.11%
Tr1w	-6.2%
Tr3m	35.11%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	9
Analyst Count Top	4
Analyst Price Target Top	$24.25
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$0.1
Earnings Revenue Estimate	152,162,704x
Earnings Revenue Estimate Growth	4.55x
Operating Income	$322.2M
Operating Income Growth	835.8
Operating margin	36.38
Price target	$21.11
Price Target Change	$145
Price Target Change Top	$181

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	221,543,490%
Float Percent	87.17%
Net Borrowing	64,937,000
Shares Insiders	0.96%
Shares Institutions	76.61%
Shares Out	254,162,660
Shares Qo Q	10.49%
Shares Yo Y	5.23%
Short Float	17.39%
Short Ratio	5.68
Short Shares	15.16

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$230.6M
Average Volume	3,905,708.25x
Bv Per Share	-2.18
CAPEX	$-2.7M
Ch10y	203.5
Ch15y	151.7
Ch1m	-10.11
Ch1w	-6.2
Ch1y	-14.48
Ch20y	-41.99
Ch3m	35.11
Ch3y	0.7
Ch5y	-34.3
Ch6m	21.58
Change	-3.15%
Change From Open	-3.79
Close	8.9
Days Gap	0.67
Depreciation Amortization	4,218,000
Dollar Volume	53,137,455.6
Earnings Date	2026-05-06
Earnings Time	bmo
EBIT	$322.2M
EBITDA	$326.5M
EPS	$-2.1
F Score	5
FCF	$310.4M
FCF EV Yield	11.04x
FCF Per Share	$1.22
Financing CF	62,092,000
Fiscal Year End	December
Founded	1,986
Income Tax	$3.8M
Investing CF	-309,437,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	7.8
Ma150ch	10.51%
Ma20	9.09
Ma20ch	-5.12%
Net CF	66,497,000
Next Earnings Date	2026-08-03
Open	8.96
Optionable	Yes
P FCF Ratio	7.06
P OCF Ratio	7
Position In Range	13.95
Post Close	8.62
Postmarket Change Percent	-0.22
Postmarket Price	$8.6
Ppne	22,985,000
Pre Close	8.9
Price Date	2026-05-08
Price EBITDA	$6.71
Relative Volume	1.58x
Revenue	885,716,000x
SBC By Revenue	9x
Share Based Comp	79,725,000
Tax By Revenue	0.43x
Tr20y	-41.99%
Tr6m	21.58%
Us State	North Carolina
Volume	6,164,438
Z Score	-1.01

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does BCRX pay a dividend?

Capital-return profile for this ticker.

Performance

BCRX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BCRX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+76.6%

Float: +87.2% of shares outstanding

Insider ownership

+1.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BCRX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

41.0

Neutral momentum band

Price vs 200-day MA

+9.3%

50/200-day relationship not available

Beta (5Y)

0.57

Less volatile than the market

Sharpe ratio

-0.25

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BCRX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current BCRX stock rating?

BioCryst Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BCRX analysis?

The full report lives at /stocks/BCRX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for BCRX?

The latest report frames BCRX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the BCRX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.